Medicin

Følg
Medical researchers at University of Calgary reviewing glioblastoma scans alongside niacin supplements for a clinical trial illustration.
Billede genereret af AI

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

Rapporteret af AI Billede genereret af AI Faktatjekket

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

A study has identified how an existing medication could improve immunotherapy outcomes for fibrolamellar carcinoma. The rare liver cancer currently has no cure and often spreads before detection. Researchers demonstrated the approach using patient tumor samples.

Rapporteret af AI Faktatjekket

A Newcastle University-led screening study of nearly 300 adults in northern Britain found persistently high rates of low vitamin D in older people and adults from minoritized ethnic groups, with little evidence that summer months substantially improved levels.

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

Rapporteret af AI

Two existing medications cooled core body temperature in animals after stroke and reduced brain damage. A small human trial showed limited effect due to slow delivery. Researchers are now planning a follow-up study with faster infusions.

Medicinalteknologivirksomheden SpectraCure i Lund gennemfører en fortegningsretsemission, der vil tilføre 34,2 millioner svenske kroner, hvis den tegnes fuldt ud. Emissionen skal finansiere kliniske studier og ansøgninger til myndighederne. Aktien faldt mere end 20 procent mandag.

Rapporteret af AI Faktatjekket

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis